Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Stock Has Average Price Target of $17.80 According to Analysts

Key Points

• Analyst sentiment is moderately bullish: Ten brokerages give Eupraxia Pharmaceuticals a consensus “Moderate Buy” rating, with an average 12-month price target of $17.80 versus the stock’s reported $6.62 opening price.
• Shares remain below recent highs: EPRX has traded between $5.25 and $9.32 over the past year, with 50-day and 200-day moving averages of $7.53 and $7.02, respectively.
• The company remains loss-making but financially well-capitalized: Eupraxia reported a quarterly loss of $0.23 per share, slightly better than expectations, while maintaining current and quick ratios of 16.00 and minimal debt relative to equity.

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $17.80.

A number of equities research analysts have recently commented on EPRX shares. Oppenheimer started coverage on Eupraxia Pharmaceuticals in a research report on Thursday, June 25th. They set an "outperform" rating and a $17.00 price target on the stock. Wedbush started coverage on Eupraxia Pharmaceuticals in a research report on Thursday, September 24th. They issued an "outperform" rating and a $17.00 price objective for the company. Stifel Nicolaus set a $25.00 price objective on Eupraxia Pharmaceuticals in a research report on Thursday, September 24th. Cantor Fitzgerald reissued an "overweight" rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, October 8th. Finally, HC Wainwright reissued a "buy" rating and set a $11.00 target price on shares of Eupraxia Pharmaceuticals in a research note on Thursday, October 1st.

Eupraxia Pharmaceuticals Stock Performance

Shares of Eupraxia Pharmaceuticals stock opened at $6.62 on Friday. The stock's fifty day simple moving average is $7.53 and its 200 day simple moving average is $7.02. The company has a current ratio of 16.00, a quick ratio of 16.00 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $430.43 million, a PE ratio of -6.49 and a beta of 0.83. Eupraxia Pharmaceuticals has a 12 month low of $5.25 and a 12 month high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.02. On average, research analysts predict that Eupraxia Pharmaceuticals will post -0.85 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Seven Fleet Capital Management LP bought a new stake in shares of Eupraxia Pharmaceuticals during the first quarter worth $5,137,000. Redmile Group LLC acquired a new stake in shares of Eupraxia Pharmaceuticals during the first quarter worth $5,068,000. Cibc World Market Inc. bought a new stake in Eupraxia Pharmaceuticals in the 2nd quarter valued at $1,539,000. Rubric Capital Management LP bought a new stake in Eupraxia Pharmaceuticals in the 1st quarter valued at $5,004,000. Finally, DV Trading LLC bought a new stake in Eupraxia Pharmaceuticals in the 1st quarter valued at $1,998,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc NASDAQ: EPRX is a Canadian clinical-stage biotechnology company focused on developing locally delivered therapies designed to treat disease at the site of action while potentially reducing systemic exposure and associated side effects. The company is headquartered in Victoria, British Columbia, and is developing candidates for inflammatory and other serious medical conditions.

Eupraxia's lead program, EP-262, is an extended-release formulation of dexamethasone being developed for the treatment of pain and inflammation associated with osteoarthritis of the knee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.